Taysha Gene Therapies (TSHA) Common Equity (2019 - 2026)

Taysha Gene Therapies has disclosed Common Equity across 8 years of filings, most recently posting $211.9 million for Q1 2026.

• Common Equity for Q1 2026 came in at $211.9 million, up 284.94% year-over-year; the trailing twelve-month figure through Mar 2026 was $211.9 million (up 284.94% YoY), and the FY2025 annual result was $246.9 million, up 245.25% from the prior year.
• Common Equity came in at $211.9 million for Q1 2026 at Taysha Gene Therapies, down from $246.9 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $248.7 million in Q2 2025 to a low of -$49.1 million in Q3 2023.
• The 5-year median for Common Equity is $55.1 million (2025), against an average of $80.8 million.
• Peak annual rise in Common Equity reached 7796.42% in 2023, while the deepest fall reached 558.88% in 2023.
• Taysha Gene Therapies' Common Equity stood at $949000.0 in 2022, then soared by 7796.42% to $74.9 million in 2023, then fell by 4.55% to $71.5 million in 2024, then soared by 245.25% to $246.9 million in 2025, then dropped by 14.17% to $211.9 million in 2026.
• The last three Common Equity figures came in at $211.9 million (Q1 2026), $246.9 million (Q4 2025), and $219.0 million (Q3 2025), per Business Quant data.